Recent studies of delta-tocotrienol on non-small cell lung cancer discovered that the anticancer activity induced by delta-tocotrienol is associated with its ability to decrease Notch-1, Hes-1, Survivin, MMP-9, VEGF, and Bcl-XL expressions, with additional decrease of binding activity in NF-κB-DNA [48, 49]. This evidence concerns the gene BCL2L1 and non-small cell lung carcinoma.